Current partner codePEPTIDESDE
NCT03598075·Not applicable·INTERVENTIONAL

Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

Status

Completed

Phase

Not applicable

Enrollment

36

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Amylin and calcitonin gene related peptide (CGRP) are related to the same peptide family. Both share 16 out of 37 amino acids and can activate each others receptor. CGRP is implicated in migraine pathophysiology but the role of Amylin and its receptor in migraine is not fully clarified.

Full detailed description

Amylin is a peptide hormone that binds to a G-protein coupled receptor (GPCR). amylin was originally found in the pancreas (Beta Cell of Islets of Langerhans) but also shown to be present in the trigeminal ganglion, hind horn ganglia and perivascular nerve fibers. Amylin has many similarities with CGRP. Amylin and CGRP share 16 out 37 amino acids. Both peptides can activate the amylin 1 subtype (AMY1)receptor with high affinity and reported to have more similar physiological and pharmacological effects. In addition, both peptides increase the intracellular concentration of cyclic AMP (cAMP) which has a central role in migraine pathophysiology. The aim of the study is pin point the role of amylin and amylin receptor compare to CGRP in migraine pathophysiology.

Interventions

Treatment arms and agents.

OTHER

Amylin (Pramlintide)

Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .

OTHER

CGRP

CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.

Timeline

From registration to results.

  1. First posted

    Jul 26, 2018

  2. Study start

    Jul 1, 2018

  3. Primary completion

    Sep 30, 2019

  4. Study completion

    Dec 31, 2019

  5. Results posted

    Not reported

  6. Registry updated

    Jun 25, 2020

Outcomes

What the study measures.

Primary outcomes

Migraine incidence

Time frame · 12 hours

Before (-10 min) and after infusion (+12 hours) of amlyin compared with before and after infusion of CGRP based on questionnaire reported headache and associated symptoms

Secondary outcomes

Dilatation of Arteria radialis and arteria temporalis superficialis

Time frame · 2 hours

Dermascan will be used to measure the above mentioned Radial and temporal arteries diameter.

Facial flushing

Time frame · 2 hours

Flushing will measured by laser contrast imaging

Plasma blood samples

Time frame · 2 hours

Measumrent of amylin and CGRP peptides in the plasma in picomol/L

Headache intensity

Time frame · 12 hours

Measured by visual analog score (VAS) ( 0 to 10). Change in area under curve (AUC)

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
60 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: * Migraine patients meeting International Headache Society (IHS) criteria for migraine without aura of both sexes, 18-60 year, 50-100 kg. * Fertile women should use safe contraception. Fertile women do not include hysterectomized women or women who are postmenopausal for at least 2 years. Safe contraception includes either Intra Uterine Device (IUD), birth control pills, surgical sterilization of the woman or depot progestogen. Exclusion Criteria: * Tension Type headache for more than 5 days the month on average in the last year. * All other primary headaches . * Headache later than 48 hours before trial start. * Daily intake of any medicine other than oral contraception. * Ingestion of any form of medicinal product later than 4 times the plasma half-life substance (on trial day), except for oral contraception. * Pregnant or breastfeeding women. * Headache on the test day or later than 48 hours prior to administration of trial medicine / placebo * Migraine within 5 days before the trial date. * Ancestral information or clinical signs of (on the day of inclusion): * Hypertension (systolic blood pressure\> 150 mmHg and / or diastolic blood pressure\> 100 mmHg) * Hypotension (systolic blood pressure \<90 mm Hg and / or diastolic blood pressure \<50 mmHg) * Cardiovascular disease of all kinds, including cerebrovascular disease. * Anamnestic or clinical signs of mental illness or abuse. * Patients with glaucoma or prostatic hyperplasia * Anamnestic or clinical signs of diseases of any kind such as the investigating physician is considered relevant for participation in the trial.

Study locations

1 registered sites.

Denmark. Showing up to 24 locations stored in the fast local snapshot.

Danish Headache Center

Glostrup Municipality, Denmark

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Pramlintide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.